Physician

Oncology

Dr. Tal Z. Zaks, MD

Zaks is an expert in the field of Oncology. Zaks has written publications. He has 24 publications published with PubMed. The lastest paper is: 'Human melanoma cells do not express Fas (Apo-1/CD95) ligand.'

Publications

Precision Medicine in the Age of Big Data: The Present and Future Role of Large Scale Unbiased Sequencing in Drug Discovery and Development.
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung ca...
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lap...
Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization.
[The immunopathological basis of asthma].
[Chloroquine for chronic interstitial pneumonia in children].
High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization.
Cancers of the large bowel and hepatobiliary tract.
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.
Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines.
TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis.
T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.
Cancer therapy using a self-replicating RNA vaccine.
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort i...
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

University of Pennsylvania Health System
Temple University Hospital

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Seyfettin O. Alpdogan, MD This Doctor is OpenDoctor Recommended.
	Dr. Naomi S. Balzer-Haas, MD This Doctor is OpenDoctor Recommended.
	Dr. Brij B. Srivastava, MD
	Dr. Muhammad Rizvi, MD This Doctor is OpenDoctor Recommended.
	Dr. Lori J. Goldstein, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. James J. Perry, MD
	Dr. Elizabeth R. Plimack, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Julia Kennedy, DO
	Dr. Bijoyesh Mookerjee, MD This Doctor is OpenDoctor Recommended.
	Dr. Elena Gitelson, MD This Doctor is OpenDoctor Recommended.
	Dr. Aruna Padmanabhan, MD This Doctor is OpenDoctor Recommended.
	Dr. Amy MacKenzie, MD This Doctor is OpenDoctor Recommended.
	Dr. Frederick M. Fellin, MD This Doctor is OpenDoctor Recommended.